Dazukibart

Phase 3Small molecule

Pfizer

Dazukibart is one of 16 small molecule programs targeting Dermatomyositis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DermatomyositisRecruiting

DermatomyositisPhase 3

Recruiting

Competition

Competitive Landscape

16 competitors in Dermatomyositis

#DrugCompanyPhaseTrials

Xeljanz

PPrism Pharmaceuticals

Approved

2 2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Olumiant

2 4

Jakafi

Incyte

Phase 2

1 5

Interleukin 2

EEssen Biotech

Phase 3

1 6

Empasiprubart

Argenx

Phase 2

1 7

Emapalumab

SSwedish Orphan Biovitrum

Phase 2

1 8

NM8074

NNovelMed Therapeutics

Phase 2

1 9

Dazukibart

Pfizer

Phase 3

1 10

KYV-101

KKyverna Therapeutics

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 3Recruiting

Dermatomyositis

NCT06698796

Clinical

Trials by Indication[1]

Dermatomyositis1 trial

A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT06698796·211 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dazukibart. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dazukibart compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dazukibart. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Dazukibart

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Dermatomyositis1 trial

References

Drug Info

Quick Facts

Related News